Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt 2020 SR
The report highlights Gedeon Richter's performance in 2020, focusing on its response to the COVID-19 pandemic, including the development of remdesivir. Key achievements include the blockbuster status of its antipsychotic drug Vraylar in the US and the transition to annual sustainability reporting. The company emphasized its vertically integrated business model to ensure supply chain resilience. Environmental highlights include a 73% waste recycling rate. Socially, the company spent HUF 2 billion on healthcare, education, and women-focused projects while maintaining its status as a top employer in Hungary.
Company: Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt
Sector: Manufacturing
Country: Hungary
Year: 2020
Type: SR
Pages: 55
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt
The report highlights Gedeon Richter's performance in 2020, focusing on its response to the COVID-19 pandemic, including the development of remdesivir. Key achievements include the blockbuster status of its antipsychotic drug Vraylar in the US and the transition to annual sustainability reporting. The company emphasized its vertically integrated business model to ensure supply chain resilience. Environmental highlights include a 73% waste recycling rate. Socially, the company spent HUF 2 billion on healthcare, education, and women-focused projects while maintaining its status as a top employer in Hungary.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees